TY - THES A1 - Li, D T1 - A physiologically based pharmacokinetic model study of the biological fate, transport and behavior of engineered nanoparticles. Y1 - 2015// N1 - R834860 ER - TY - JOUR A1 - Carlander, U A1 - Li, D A1 - Jolliet, O A1 - Emond, C A1 - Johanson, G T1 - Toward a general physiologically-based pharmacokinetic model for intravenously injected nanoparticles. Y1 - 2016/02/11 N1 - R834860 JF - INTERNATIONAL JOURNAL OF NANOMEDICINE VL - 11 SP - 625 EP - 640 ER - TY - JOUR A1 - Fatouraie, M A1 - Eagle, W E A1 - Li, D A1 - Morishita, M A1 - Barres, J A1 - Wagner, J G A1 - Jolliet, O A1 - Wooldridge, M S T1 - Combustion synthesis of CeO2 nanoparticles for aging and inhalation exposure studies. Y1 - 2017/04/ N1 - R834860 JF - JOURNAL OF AEROSOL SCIENCE J1 - J AEROSOL SCI J2 - J.Aerosol Sci. VL - 106 SP - 24 EP - 33 ER - TY - JOUR A1 - Li, D A1 - Emond, C A1 - Johanson, G A1 - Jolliet, O T1 - Using a PBPK model to study the influence of different characteristics of nanoparticles on their biodistribution. Y1 - 2013/04/ N1 - R834860 JF - JOURNAL OF PHYSICS:CONFERENCE SERIES VL - 429 IS - 1 SP - 012019 ER - TY - JOUR A1 - Li, D A1 - Johanson, G A1 - Emond, C A1 - Carlander, U A1 - Philbert, M A1 - Jolliet, O T1 - Physiologically based pharmacokinetic modeling of polyethylene glycol-coated polyacrylamide nanoparticles in rats. Y1 - 2014/08/ N1 - R834860 JF - NANOTOXICOLOGY J1 - Nanotoxicology VL - 8 IS - S1 SP - 128 EP - 137 ER - TY - JOUR A1 - Li, D A1 - Morishita, M A1 - Wagner, J G A1 - Fatouraie, M A1 - Wooldridge, M A1 - Eagle, W E A1 - Barres, J A1 - Carlander, U A1 - Emond, C A1 - Jolliet, O T1 - In vivo biodistribution and physiologically based pharmacokinetic modeling of inhaled fresh and aged cerium oxide nanoparticles Y1 - 2016/08/20 N1 - R834860 JF - PARTICLE AND FIBRE TOXICOLOGY VL - 13 IS - 1 SP - 45 ER - TY - JOUR A1 - Wenger, Y A1 - Schneider Jr., R J A1 - Reddy, G R A1 - Kopelman, R A1 - Jolliet, O A1 - Philbert, M A T1 - Tissue distribution and pharmacokinetics of stable polyacrylamide nanoparticles following intravenous injection in the rat. Y1 - 2011/03/15 N1 - R834860 VL - 251 IS - 3 SP - 181 EP - 190 ER - TY - CONF A1 - Bumbalough, E A1 - Eagle, W E A1 - Wooldridge, M S T1 - Combustion synthesis of cerium dioxide from cerium(III) acetate in a multi-element diffusion flame. Y1 - 2012/04/22-24 N1 - R834860 ER - TY - CONF A1 - Eagle, W A1 - Wooldridge, M T1 - Combustion synthesis of cerium dioxide from cerium (III) acetate in a multi-element diffusion flame. Y1 - 2012/11/26-30 N1 - R834860 ER - TY - CONF A1 - Jolliet, O T1 - Life cycle risks and impacts of nanotechnologies. Y1 - 2012/11/16 N1 - R834860 ER - TY - CONF A1 - Jolliet, O T1 - Direct human health and ecosystem impacts of nanoparticles in LCA. Y1 - 2015/05/3-7 N1 - R834860 ER - TY - CONF A1 - Li, D A1 - Emond, C A1 - Johanson, G A1 - Jolliet, O T1 - PBPK modeling of polyacrylamide nanoparticle biodistribution in rats. Y1 - 2011/10/23-27 N1 - R834860 ER - TY - CONF A1 - Li, D A1 - Emond, C A1 - Johanson, G A1 - Jolliet, O T1 - PBPK modeling of polyacrylamide nanoparticle biodistribution in rats. Y1 - 2012/03/11-15 N1 - R834860 ER - TY - CONF A1 - Li, D A1 - Johanson, G A1 - Emond, C A1 - Carlander, U A1 - Jolliet, O T1 - Influence of size and surface modifications of nanoparticles on their uptake and biodistribution. Y1 - 2012/05/20-24 N1 - R834860 ER - TY - CONF A1 - Li, D A1 - Emond, C A1 - Johanson, G A1 - Jolliet, O T1 - Using a PBPK model to study the influence of different characteristics of nanoparticles on their biodistribution. Y1 - 2012/11/13-15 N1 - R834860 ER - TY - CONF A1 - Li, D A1 - Emond, C A1 - Johanson, G A1 - Jolliet, O T1 - PBPK modeling of nanoparticles in rats. Y1 - 2012/11/15 N1 - R834860 ER - TY - CONF A1 - Li, D A1 - Johanson, G A1 - Emond, C A1 - Carlander, U A1 - Jolliet, O T1 - Influence of size and surface modifications of nanoparticles on their uptake and biodistribution. Y1 - 2012/10/28-1 N1 - R834860 ER - TY - CONF A1 - Li, D A1 - Johanson, G A1 - Emond, C A1 - Jolliet, O T1 - Physiologically based pharmacokinetic modeling of cerium oxide nanoparticles in rats. Y1 - 2013/08/20-23 N1 - R834860 ER - TY - CONF A1 - Li, D A1 - Johanson, G A1 - Emond, C A1 - Carlander, U A1 - Jolliet, O T1 - Physiologically based pharmacokinetic modeling of cerium oxide nanoparticles in rats. Y1 - 2013/08/20-23 N1 - R834860 ER - TY - CONF A1 - Li, D A1 - Johanson, G A1 - Emond, C A1 - Carlander, U A1 - Jolliet, O T1 - Physiologically based pharmacokinetic modelling of polyethylene glycol-coated plyacrylamide nanoparticle in rats. Y1 - 2013/05/12-16 N1 - R834860 ER - TY - CONF A1 - Li, D A1 - Johanson, G A1 - Emond, C A1 - Carlander, U A1 - Jolliet, O T1 - Physiologically based pharmacokinetic modelling of polyethylene glycol-coated polyacrylamide nanoparticle in rats. Y1 - 2013/05/12-16 N1 - R834860 ER - TY - CONF A1 - Li, D A1 - Barres, J A1 - Carlander, U A1 - Eagle, E A1 - Emond, C A1 - Johanson, G A1 - Morishita, M A1 - Wagner, J G A1 - Wooldridge, M A1 - Jolliet, O T1 - Physiologically based pharmacokinetic modeling of cerium oxide nanoparticles by pulmonary exposure in rats. Y1 - 2014/05/24-27 N1 - R834860 ER - TY - CONF A1 - Li, D A1 - Barres, J A1 - Eagle, E A1 - Emond, C A1 - Morishita, M A1 - Wagner, J G A1 - Wooldridge, M A1 - Jolliet, O T1 - Physiologically based pharmacokinetic modeling of cerium oxide nanoparticles by inhalation exposure in rats. Y1 - 2014/10/12-16 N1 - R834860 ER - TY - CONF A1 - Li, D A1 - Barres, J A1 - Eagle, E A1 - Emond, C A1 - Fatouraie, M A1 - Morishita, M A1 - Wagner, J G A1 - Wooldridge, M A1 - Jolliet, O T1 - In vivo biodistribution and physiologically based pharmacokinetic modeling of inhaled fresh and aged cerium oxide nanoparticles. Y1 - 2015/10/18-22 N1 - R834860 ER - TY - CONF A1 - Morishita, M A1 - Jolliet, O A1 - Li, L A1 - Wooldridge, M A1 - Eagle, E A1 - Bumbalough, E A1 - Wagner, J A1 - Harkema, J A1 - Emond, C T1 - Environmental transformation and biological fate of fresh and aged cerium oxide nanoparticles. Y1 - 2013/10/28-31 N1 - R834860 ER -